547 evidence-based articles, checked against primary sources.

A warm, honest, evidence-graded guide to sex after menopause: why dryness, pain and low desire happen, and which fixes are proven — from lubricants and moisturizers to low-dose vaginal estrogen — versus which are mostly marketing.

Most people eating normally don't need electrolyte packets. Here's how to read sodium, potassium, magnesium, and sugar per serving against your own situation — who genuinely benefits, who should be cautious, and why plain water (or a homemade mix) is often the honest answer.

NMN and NR reliably raise NAD+ in your blood — but no human trial shows the anti-aging, energy, or metabolic benefits that sell them. An honest evidence grade.

Why midlife estrogen changes can worsen or reveal ADHD — the real evidence, what HRT can and cannot do, and a symptom-by-symptom guide to telling perimenopause and ADHD apart.

Most healthy women over 50 don't need a cabinet full of pills. This honest guide covers the nutrients that genuinely matter after menopause—vitamin D, B12, omega-3s, and iron only if you're deficient—plus a checklist for spotting a quality, third-party-tested supplement.

A buyer's guide to fish oil and omega-3 supplements built on independent certification and clinical evidence — not affiliate hype. Learn the EPA+DHA number that matters, the seals worth trusting (USP, NSF, IFOS), why freshness is the hidden problem, and who should check with a clinician first.

A buyer's guide to choosing a quality magnesium supplement: match the form to your goal (glycinate, citrate, oxide, malate, threonate — graded honestly), then screen for USP or NSF third-party testing, elemental-magnesium labeling, no proprietary blends, and a safe dose within the 350 mg supplemental ceiling. Includes registry-verified certified examples and who should be cautious.

GLP-1 weight loss is a year-plus arc, not a quick fix. Here's what really happens month by month — appetite changes, dose step-ups, when most weight lands, why the plateau is normal, and what the trials show about stopping.

What survodutide is, how its dual GLP-1/glucagon action targets both weight and the liver, what mid-stage and early phase 3 trials actually showed, and why it remains investigational and not prescribable.

Mazdutide is a once-weekly GLP-1 and glucagon receptor dual agonist, approved for weight management in China in 2025 but investigational and unavailable in the US. Here's the verified trial evidence, its standout liver-fat signal, and what it may mean for midlife metabolic health.

GLP-1 drugs mimic a gut hormone to curb appetite and steady blood sugar. This hub explains the FDA-approved options, who qualifies, real trial results, cost and coverage, side effects, and what women in midlife specifically need to know — then routes you to the right deep dive.

CagriSema pairs cagrilintide (an amylin analog) with semaglutide (a GLP-1) in one weekly injection. Here is the honest picture: what it is, where it stands with the FDA, what the REDEFINE trials actually showed, and how it compares with tirzepatide — without the hype.

As of January 2026, about 13 state Medicaid programs cover GLP-1 drugs for obesity while nearly all cover them for type 2 diabetes. Roughly 80% of adult Medicaid enrollees live in states with no obesity pathway. Medicare is barred by law from covering obesity-only drugs. This citable report pulls together the KFF, CMS, and FDA figures behind the 2026 coverage map.

Tirzepatide's FDA label warns it can make oral birth control less effective; semaglutide's does not. We break down why, which methods are unaffected, and what the labels actually advise — without telling you to start or stop anything.

No GLP-1 is FDA-approved for PCOS — its use is off-label. Weight loss is the best-documented benefit; effects on cycles, ovulation, and hormones are still emerging. Plus the fertility and contraception cautions every woman should know.

The theoretical worry is real, but the trial data so far are reassuring — and the practical answer is the same plan that protects your muscle.

GLP-1 “microdosing” means deliberately taking doses far below the approved range, usually from compounded vials. It is not an FDA-recognized or studied approach, and experts are wary because sub-therapeutic, self-measured dosing raises real risks without proven benefit.

Is it safe to drink alcohol on a GLP-1 like Ozempic, Wegovy, or Zepbound? An honest, evidence-graded look at side effects, blood-sugar risk, contraception, and the semaglutide-alcohol craving trials.